Z. SEZER Et Al. , "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up," Vaccines , vol.12, no.2, 2024
SEZER, Z. Et Al. 2024. Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up. Vaccines , vol.12, no.2 .
SEZER, Z., PAVEL, S. T. I., İNAL, A., YETİŞKİN, H., KAPLAN, B., UYGUT, M. A., ... ASLAN, A. F.(2024). Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up. Vaccines , vol.12, no.2.
SEZER, ZAFER Et Al. "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up," Vaccines , vol.12, no.2, 2024
SEZER, ZAFER Et Al. "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up." Vaccines , vol.12, no.2, 2024
SEZER, Z. Et Al. (2024) . "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up." Vaccines , vol.12, no.2.
@article{article, author={ZAFER SEZER Et Al. }, title={Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up}, journal={Vaccines}, year=2024}